Paradigm Biopharmaceuticals Limited

Equities

PAR

AU000000PAR5

Biotechnology & Medical Research

Delayed Australian S.E. 01:56:09 2024-05-20 am EDT 5-day change 1st Jan Change
0.26 AUD -3.70% Intraday chart for Paradigm Biopharmaceuticals Limited -3.70% -38.82%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Paradigm Biopharma's Injectable Pentosan Polysulfate Sodium Trial Reaches Endpoint MT
Paradigm Biopharmaceuticals Secures AU$7 Million R&D Tax Incentive Rebate for Fiscal Year 2023; Shares Rally 9% MT
Paradigm Biopharmaceuticals Opens Retail Entitlement Offer MT
Paradigm Biopharmaceuticals Raising AU$30 Million for Clinical Trial MT
Paradigm Biopharmaceuticals Ltd Announces Resignation of John Gaffney as Independent Non Executive Director, Effective Immediately CI
Paradigm Biopharmaceuticals Validates Cartilage Preservation in Knee Osteoarthritis Trial MT
Paradigm Biopharmaceuticals Confirms Effectivity of Pain Medication in Osteoarthritis Trial MT
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023 CI
Paradigm Biopharmaceuticals Validates Efficacy of Anti-Inflammatory Medication in Canine Trial MT
Paradigm Biopharmaceuticals Announces Phase 2 Trial in Osteoarthritis Shows Signs of Disease Modification At 6-Month Follow-Up CI
Paradigm Biopharmaceuticals Limited Announces Injectable PPS Demonstrates Multiple Signals of A DMOAD in PARA_OA_008 Phase 2 Clinical Study CI
Paradigm Biopharmaceuticals Secures European Ethics Approval for Knee Osteoarthritis Trial MT
Paradigm Biopharmaceuticals Ltd Receives European Regulatory and Ethics Approval for the Pivotal PARA_OA_002 Global Clinical Trial CI
Starpharma Appoints CFO MT
Paradigm Biopharmaceuticals Names Interim CFO MT
Paradigm Biopharmaceuticals Limited Announces the Change of Chief Financial Officer CI
Paradigm Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022 CI
Lingering Concerns on Economic Outlook, Rate Hikes Dampen Appetite for Australian Shares MT
Paradigm Biopharmaceuticals Secures Go-Signal to Advance Phase 3 Osteoarthritis Trial MT
Paradigm Biopharmaceuticals Ltd Advises the First Safety Review Meeting of the Data Monitoring Committee for the Pivotal Para_OA_002 Clinical Trial CI
Paradigm Biopharmaceuticals Moves Closer to US Patent Approval for Bone Marrow Treatment MT
Paradigm Biopharmaceuticals CEO to Step Down; Shares Fall 11% MT
Paradigm Biopharmaceuticals Limited Announces Executive Changes CI
Chart Paradigm Biopharmaceuticals Limited
More charts
Paradigm Biopharmaceuticals Limited is a late-stage drug development company. It is engaged in researching and developing therapeutic products for human use. It is focused on the development of injectable pentosan polysulfate sodium (iPPS/PPS) for the treatment of osteoarthritis (OA). Pentosan polysulfate sodium is a semi-synthetic drug manufactured from the wood chips of European beech trees. Extracted glucurono-xylans are sulfated to produce a negatively charged product that mimics glycosaminoglycans (GAGs). It develops PPS under the brand name Zilosul. PPS clears cellular and tissue accumulation of GAGs. PPS also inhibits the synthesis of the metalloproteinase, MMP-3 (Troeberg) involved in degrading cartilage. PPS also include treatment of joint function, mobility, and pain in patients with mucopolysaccharidoses (MPS); treating alphavirus-induced arthralgia (such as Ross River virus and Chikungunya); chronic heart failure (HF) and acute respiratory distress syndrome (ARDS).
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.27 AUD
Average target price
3.19 AUD
Spread / Average Target
+1,081.48%
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. PAR Stock
  4. News Paradigm Biopharmaceuticals Limited
  5. Paradigm Biopharmaceuticals Submits Documents to FDA for Phase 3 Osteoarthritis Program
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW